Clinical trials: Cancer, Bladder
Bladder Cancer
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00089128
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Medical University of South Carolina
Colorectal Cancer, Bladder Cancer
Connecting Audio and Radio Sensing Systems to Improve Care at Home
This study aims to assess the usability of the innovative Audio + Radio (AURA) system in enhancing personalized supportive care for cancer patients and caregivers during the post-ostomy care transition by collecting information…
- Conditions
- Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- AURA (NCT05344950)
- Testing
- Audio + Radio (AURA)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Breast Cancer, Treatment-Refractory Solid Tumors
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: Patients with advanced breast cancer that has become worse after taking palbociclib alone Patients with…
- Conditions
- Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC
- Trial name
- NCT05655598
- Testing
- Palbociclib Oral Product, TAS-116
- Where
- United States
- Sponsor
- Brown University
Bladder Cancer
(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
Single-arm, open-label window-of-opportunity trial of neoadjuvant Abemaciclib in 20 patients, with tumor tissue obtained as standard of care at tumor resection (pre-Abemaciclib) and cystectomy (post-Abemaciclib)
- Trial name
- CLONEVO (NCT03837821)
- Testing
- Abemaciclib
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Urinary Bladder Neoplasms
A Study of Radical Cystectomy in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC) in Korea
The purpose of this study is to assess participant's overall well-being and the extent to which medical services are used by participants with non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC)…
- Trial name
- BC RC DB (NCT07735793)
- Volunteers
- 1 people
- Sponsor
- Janssen Korea, Ltd., Korea
Bladder Cancer, Bladder Urothelial Carcinoma
Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy
In view of sparse data of precise definition, risk factors, natural history and management of bladder perforation following Transurethral resection of bladder tumour (TURBT).
- Conditions
- Bladder Cancer, Bladder Urothelial Carcinoma, Trauma, Injuries
- Trial name
- TURBT-BP (NCT04129606)
- Testing
- Computed tomographic cystography
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Abdelwahab Hashem
Cancer of the Bile Duct, Gallbladder Cancer
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
The purpose of this clinical trial is to determine whether the combination of the established chemotherapeutic agent 5-fluorouracil(5-FU) and the large carbohydrate molecule GM-CT-01 is beneficial in treating advanced gall…
- Trial name
- NCT00386516
- Testing
- GM-CT-01, 5-Fluorouracil
- Where
- 3 sites in United States
- Sponsor
- Galectin Therapeutics Inc.
Bladder Cancer
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
To our knowledge, there are no comparative studies on bacillus Calmette-Guerin (BCG) and intravesical chemotherapy addressing quality of life (QoL) issues.
- Trial name
- NCT01697306
- Testing
- Gemcitabine 2 g, BCG Vaccine
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Muscle Invasive Bladder Cancer
Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer
Your text is mostly clear and well-structured. Here's a slightly polished version for improved clarity and flow: This is a randomized, non-inferiority study comparing radiochemotherapy to radical cystectomy in patients with…
- Trial name
- REDEMPTED (NCT07008833)
- Testing
- Radiochemotherapy, Radical cystectomy
- Where
- Brazil
- Volunteers
- 336 people
- Sponsor
- Brazilian Clinical Research Institute
Cervical Cancer, Lung Cancer
Internet-based System for Cancer Patients to Self-report Toxicity
Cancer patients may develop side effects during treatment, such as nausea, pain, fatigue, diarrhea, constipation, or shortness of breath.
- Conditions
- Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer
- Trial name
- NCT00578006
- Testing
- Questioners, STAR website
- Where
- United States
- Volunteers
- 1,007 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
This is a prospective, open, single-center clinical study of the anti-HER2(Human epidermal growth factor receptor-2) ADC(antibody-drug conjugate) drug Disitamab Vedotin in combination with BCG(bacillus Calmette-Guerin) therapy in…
- Trial name
- NCT06187506
- Testing
- Disitamab vedotin, Bacillus Calmette Guerin Vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
NMIBC, TCC
1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors
to compare pathological and oncological outcomes of TURBT versus ERBT in patients with bladder tumors sizes >2.5cm.
- Trial name
- NCT07898033
- Testing
- En Bloc Resection of Bladder Tumor, Trans Urethral Resection of Bladder Tumor
- Where
- Israel
- Volunteers
- 136 people
- Sponsor
- dmitry enikeev
Non Muscle Invasive Bladder Cancer
Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBT
This is a prospective, open-label, single-center, single-arm phase II clinical study to evaluate the efficacy and safety of toripalimab combined with intravesical gemcitabine as adjuvant therapy in patients with high-risk…
- Trial name
- NCT07808216
- Testing
- Toripalimab (JS001 ), Gemcitabine (GEM)
- Volunteers
- 54 people
- Sponsor
- Tianjin First Central Hospital
Radical Cystectomy, Muscle-Invasive Bladder Carcinoma
Clinical Utility of VI-RADS in Diagnosis of MIBC
Bladder Cancer (BCa) is the 9th most common cancer worldwide. In general, BCa is presented as a non-muscle invasive bladder cancer (NMIBC) in 70% of patients and treated with transurethral resection of bladder tumor (TUR-BT).
- Conditions
- Radical Cystectomy, Muscle-Invasive Bladder Carcinoma, Multiparametric MRI, Vesical Imaging Report and Data System
- Trial name
- NCT05097404
- Where
- South Korea
- Volunteers
- 73 people
- Sponsor
- Samsung Medical Center
Muscle Invasive Bladder Cancer
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
This is a multi-center Phase II study to determine the safety and efficacy of nivolumab when given in combination with cisplatin and gemcitabine as neoadjuvant treatment in patients with muscle-invasive bladder cancer (MIBC)…
- Trial name
- NCT03294304
- Testing
- Nivolumab, Cisplatin, Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Prostate Cancer, Bladder Cancer
DRG Mutations in Prostate Cancer: a Guiding Light for Enhanced Screening and Personalised Therapy
At the present moment, there is no international consensus on the optimal screening to perform in men with a specific genetic/molecular risk for PCa.
- Trial name
- NCT07265414
- Testing
- Screening Platform
- Where
- Italy
- Volunteers
- 320 people
- Sponsor
- Istituto Clinico Humanitas
Bladder Urothelial Carcinoma, Bladder Cancer
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
This is a multicenter, prospective, open-label, Phase II, four-arm parallel study evaluating the efficacy and safety of different sensitization strategies combined with disitamab vedotin and toripalimab in patients with…
- Trial name
- SYSTEM (NCT07717242)
- Testing
- Disitamab vedotin, Toripalimab, Sitagliptin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bladder Cancer
Urine Cytology and Utility in Bladder Recurrence
Review bladder cancer patients and form a database in regards to urine cytology.
- Trial name
- NCT00971256
- Volunteers
- 10 people
- Sponsor
- Corewell Health East
Transitional Cell Carcinoma of Bladder
PF-03446962 in Relapsed or Refractory Urothelial Cancer
Salvage chemotherapy for advanced urothelial cancer (UC) yields suboptimal response rates of 15-40%, a median progression-free survival of 2-4 months and a median overall survival of 6 months.
- Trial name
- NCT01620970
- Testing
- PF03446962
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 747 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology